Article Details
Retrieved on: 2024-07-27 06:41:18
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the FDA approval of Sun Pharma's JAK inhibitor Leqselvi for treating alopecia areata. Business intelligence highlights include market forecasts, safety concerns, and the potential $253m revenue by 2030.
Article found on: www.pharmaceutical-technology.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here